Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia | Zendy

Robert Strengen Bigseth | Zendy; Håkon Sandholdt | Zendy; Andreas Petersen | Zendy; Christian Østergaard | Zendy; Thomas Benfield | Zendy; Louise Thorlacius-Ussing | Zendy

Open Access

Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia

Author(s) -

Robert Strengen Bigseth,

Håkon Sandholdt,

Andreas Petersen,

Christian Østergaard,

Thomas Benfield,

Louise Thorlacius-Ussing

Publication year - 2022

Publication title -

microbiology spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.502

H-Index - 51

ISSN - 2165-0497

DOI - 10.1128/spectrum.01530-21

Subject(s) - medicine , cefuroxime , piperacillin/tazobactam , hazard ratio , bacteremia , propensity score matching , confidence interval , methicillin resistant staphylococcus aureus , tazobactam , retrospective cohort study , proportional hazards model , antibacterial agent , surgery , piperacillin , staphylococcus aureus , antibiotics , microbiology and biotechnology , antibiotic resistance , genetics , bacteria , pseudomonas aeruginosa , biology , imipenem

This multicenter retrospective matched cohort study evaluated the effect of empirical antimicrobial therapy on the clinical outcome of methicillin-susceptibleStaphylococcus aureus bacteremia (MS-SAB) in >1100 adult patients. To the best of our knowledge, this is the largest study to date evaluating the effect of empirical treatment on the MS-SAB outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research